Abstract:Capecitabine is currently used as a treatment for advanced breast cancer. However, hand-foot syndrome (HFS) occurs in almost 50% of capecitabine-treated patients. We intervened a total of 60 patients by soaking the enrolled patients soaked each hand or foot in a novel soaking solution (normal saline (10 0 0 ml) + vitamin B12 (60 0 0 IU) + gentamicin (320 mg) + dexamethasone (10 mg)) or placebo for 15 minutes three times a day and the result suggested that a novel soaking solution was an effective method to relieve the symptoms of HFS. Background: Hand-foot syndrome (HFS) is a common adverse event in patients receiving capecitabine therapy for breast cancer, and the symptoms of HFS significantly impair patient quality of life. However, currently there are no effective drugs or measures to prevent and alleviate the occurrence of HFS.Aim: To assess the effectiveness of a novel soaking solution, a mixture solution of dexamethasone, gentamicin and vitamin B12, in patients with grade 2-3 HFS after capecitabine treatment for breast cancer. Materials and Methods: Patients with grade 2-3 HFS according to the National Cancer Institute Common Terminology Cr iter ia for Adverse Events (CTCAE) were enrolled in this randomized, single-center, self-controlled trial. Each patient's right and left hands or feet were individually randomized to soak in either a novel soaking solution (treated hands or feet) or a placebo liquid (control hands or feet) for three times a day, each time for 15 minutes and for four weeks. Effectiveness was evaluated according to CTCAE grades, defined as a reduction of 1 or more CTCAE grades. Results: A total of 60 patients were enrolled. The HFS CTCAE grade of the treated hands and feet at 4 weeks of HFS treatment was significantly decreased compared to that of the control hands and feet ( P = .005). Significant differences were also observed between the treatment conditions in terms of the HFS effectiveness rate: treated group 80% and placebo group 51.7% ( P = .001). No adverse or unexpected events were observed during the whole trial. Conclusion: Soaking affected hands or feet in a novel soaking solution safely and effectively reduced the severity of HFS following treatment with capecitabine for breast cancer.

Preventive Effects of Phenolic Compound Extra Virgin Olive Oil (EVOO) on the Incidence of Hand Foot Syndrome Induced Capecitabine

Hand-foot Syndrome Related to Chemotherapy

Possible Pathways of Capecitabine-Induced Hand-Foot Syndrome.

Possible Pathways of Capecitabine-Induced Hand–Foot Syndrome

The Effect of COX-2 Inhibitor on Capecitabine-Induced Hand–foot Syndrome in Patients with Stage II/III Colorectal Cancer: a Phase II Randomized Prospective Study

Celecoxib Can Prevent Capecitabine-Related Hand-Foot Syndrome in Stage II and III Colorectal Cancer Patients: Result of a Single-Center, Prospective Randomized Phase III Trial.

Hand-foot syndrome caused by capecitabine: incidence, risk factors and the role of dermatological evaluation

The effect of TJ-28 (Eppikajutsuto) on the prevention of hand-foot syndrome using Capecitabine for colorectal cancer: The Yokohama Clinical Oncology Group Study (YCOG1102)

Hand-foot syndrome and nail changes caused by capecitabine chemotherapy

Risk factors of capecitabine-induced hand-foot syndrome: a single-institution, retrospective study

Chemotherapy-induced hand foot syndrome: comparative efficacy and safety of pharmacological prophylaxis – systematic review and Bayesian network meta-analysis

Hand–foot syndrome induced by chemotherapy drug: Case series study and literature review

Effect of Chinese herbal compound LC09 on patients with capecitabine-associated hand-foot syndrome: A randomized, double-blind, placebo-controlled trial

Effect of a Novel Soaking Solution Used in Patients with Hand-Foot Syndrome As a Result of Capecitabine Treatment: A Randomized and Self-Controlled Trial.

Capecitabine induces hand-foot syndrome through elevated thymidine phosphorylase-mediated locoregional toxicity and GSDME-driven pyroptosis that can be relieved by tipiracil

Prophylactic strategies for hand-foot syndrome/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials

Risk Factors Exacerbating Hand-Foot Skin Reaction Induced by Capecitabine plus Oxaliplatin with or without Bevacizumab Therapy

Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial

Effect of Chinese Herbal Compound LC09 on Patients With Capecitabine-Associated Hand-Foot Syndrome: A Randomized, Double-Blind, and Parallel-Controlled Trial

Hand-foot syndrome in cancer patients on capecitabine: examining prevalence, impacts, and associated risk factors at a cancer centre in Malaysia

Oral hyperpigmentation as an initial clinical aspect of hand foot syndrome